Nexvet Biopharma Plc (NVET) Stock Price & Overview

NASDAQ:NVET

6.72

0 (0%)

Last: Jul 28, 2017, 11:58 PM

Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

The current stock price of NVET is 6.72 null. Today NVET is down by 0%. In the past month the price increased by 0.75%. In the past year, price increased by 27.03%.

NVET Key Statistics

52-Week Range2.75 - 6.76

1-Month Range6.66 - 6.72

Market Cap: 80.102M
P/E: N/A
Fwd P/E: N/A
EPS (TTM): -1.75
Dividend Yield: N/A

NVET Stock Performance

Today

1 Week

+0.30%

1 Month

+0.75%

3 Months

+1.82%

Longer-term

6 Months +100.00%

1 Year +27.03%

2 Years N/A

3 Years N/A

5 Years N/A

10 Years N/A

NVET Stock Chart

Nexvet Biopharma Plc / NVET Daily stock chart

NVET Technical Analysis

ChartMill assigns a technical rating of 7 / 10 to NVET. When comparing the yearly performance of all stocks, NVET is one of the better performing stocks in the market, outperforming 76.91% of all stocks.

Chartmill TA Rating

Chartmill Setup Rating

NVET Full Technical Analysis Report

NVET Fundamental Analysis

ChartMill assigns a fundamental rating of 3 / 10 to NVET. No worries on liquidiy or solvency for NVET as it has an excellent financial health rating, but there are worries on the profitability.

Chartmill FA Analysis

Valuation

Growth

Profitability

Health

Dividend

NVET Full Fundamental Analysis Report

NVET Earnings

Next Earnings DateN/A

Last Earnings DateN/A

NVET Earnings History

NVET Forecast & Estimates

Analysts

AnalystsN/A

Price TargetN/A

EPS Next Y-4.17%

Revenue Next YearN/A

NVET Forecast & Estimates

NVET Financial Highlights

Over the last trailing twelve months NVET reported a non-GAAP Earnings per Share(EPS) of -1.75. The EPS decreased by -4.17% compared to the year before.

Income Statements

Revenue(TTM)N/A

Net Income(TTM)N/A

		Industry Rank	Sector Rank
PM (TTM)	100.17%
ROA	-63.8%
ROE	-72.73%
Debt/Equity	0

Chartmill High Growth Momentum

EPS Q2Q%-100%

Sales Q2Q%N/A

EPS 1Y (TTM)-4.17%

Revenue 1Y (TTM)N/A

NVET financials

NVET Ownership

Ownership

Inst Owners48.38%

Shares11.92M

FloatN/A

Ins Owners15.3%

Short Float %N/A

Short RatioN/A

NVET Ownership

About NVET

Company Profile

NexvetBiopharma plc is a biopharmaceutical company. The company is focused on transforming the therapeutic market for companion animals by developing and commercializing novel biologic therapies. Its product candidate consists of NV-01, is a mAb for the control of pain associated with osteoarthritis in dogs, NV-02, is a mAb for the control of pain associated with degenerative joint disease in cats and NV-08, is a receptor fusion protein for the treatment of chronic inflammatory diseases. NexvetBiopharma plc is headquartered in Blackrock, Ireland.

Company Info

Nexvet Biopharma Plc

UNIT 5 SRAGH TECHNOLOGY PARK RAHAN ROAD

TULLAMORE L2 R35 FR98

CEO: Mark Heffernan

Phone: 353-57-932-4522

Nexvet Biopharma Plc / NVET FAQ

What does NVET do?

What is the stock price of Nexvet Biopharma Plc today?

The current stock price of NVET is 6.72 null.

Does NVET stock pay dividends?

NVET does not pay a dividend.

What is the ChartMill rating of Nexvet Biopharma Plc stock?

NVET has a ChartMill Technical rating of 7 out of 10 and a ChartMill Fundamental rating of 3 out of 10.

What is Nexvet Biopharma Plc worth?

Nexvet Biopharma Plc (NVET) has a market capitalization of 80.10M null. This makes NVET a Micro Cap stock.